Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00948961 · ClinicalTrials.gov registry record · Phase 1
A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1
A Phase 1 study, sponsored by Celldex Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 70
- Enrollment target
NCT00948961 is a Phase 1 study that has completed, run by Celldex Therapeutics. The registered enrollment target is 70 participants.
The verdict
NCT00948961, a Phase 1 study, has completed, sponsored by Celldex Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 70 participants
- Enrollment target
Study Summary
The main purpose of this study is to examine the safety and tolerability of CDX-1401 when given in combination with an immune stimulant (resiquimod) to patients with advanced cancers that are known to express the NY-ESO-1 protein.
Interventions
- BIOLOGICAL CDX-1401 in combination with Resiquimod and/or Poly-ICLC
- BIOLOGICAL CDX-1401
- BIOLOGICAL Resiquimod
- BIOLOGICAL poly-ICLC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2009-09 |
| Est. Completion | 2014-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00948961
The ClinicalTrials.gov registry entry for NCT00948961 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celldex Therapeutics, which has 42 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which CDX-1401 in combination with Resiquimod and/or Poly-ICLC is the first listed.
NCT00948961 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00948961 about?
NCT00948961 is a clinical study titled "A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1". The main purpose of this study is to examine the safety and tolerability of CDX-1401 when given in combination with an immune stimulant (resiquimod) to patients with advanced cancers that are known to express the NY-ESO-1 protein.
What is the current status of trial NCT00948961?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 70 participants. The study started on 2009-09. Estimated completion is 2014-02.
What interventions are being tested in trial NCT00948961?
The interventions under investigation include: CDX-1401 in combination with Resiquimod and/or Poly-ICLC (BIOLOGICAL), CDX-1401 (BIOLOGICAL), Resiquimod (BIOLOGICAL), poly-ICLC (BIOLOGICAL).
Who is sponsoring clinical trial NCT00948961?
This trial is sponsored by Celldex Therapeutics, which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.